Highly-validated screening assays developed by Metrion are capable of confidently identifying modulators of the lysosomal TRPML1 channel.

Improve efficiency, reduce late-stage failures, and align with regulatory standards by assessing the proarrhythmic liability of your compounds early.

A stable cell line expressing KV3.1 V434L variant was developed and characterised, confirming published data describing V434L as a gain-of-function mutation.

Manual patch-clamp technique was used to evaluate channel pharmacology using cells transiently transfected with wild-type and V434L mutant channel.

This webinar presents the patient perspective, electrophysiological research, and technologies used as we work towards a potential treatment for KCNC1-related disorders.

Presented at the SPS meeting in September 2024, Dr Steve Jenkinson presents Metrion’s human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay, an advanced tool, providing key advantages, for early cardiac derisking in drug discovery.

Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity, Genetic Engineering News. 2024 44:5, 48-50

The HESI Cardiac Safety Committee present results from an international ion channel research study that assessed the variability of hERG data generated using automated patch clamp platforms (QPatch 48, Qube 384 and the SyncroPatch 384i) across four different labs.

We developed a high-throughput, electrophysiological assay of TREK-1 function to identify novel modulators. The assay was optimized to identify both activators and inhibitors, providing comprehensive mechanistic data for high value, limited supply screening libraries, such as the venom fraction library used in this study (Targeted Venom Discovery Array, T-VDA, Venomtech, UK).

Highly specialised and tailored neuronal assays for pharmacological screening.